에 대한 최신 뉴스 ODDITY Tech (NASDAQ:ODD) 주식

ODDITY Tech

ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.

PonyAIFremont,,Ca,,Usa,-,Feb,28,,2020:,Autonomous,Driving,Startup

Equities

Mid Cap

News

Movers

CGON

FTDR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IRTC

KNSA

MTSR

PONY

PRDO

포니AI·힘스핸허스 등 지난주 급등한 중형주 11종목 (4월 28일~5월 2일) 오디티 테크, 멧세라, CG 온콜로지, 키닉사 파마슈티컬스, 킹소프트, 프론트도어, ATI, 퍼도세오, 아이리듬

포니AI·힘스앤허스 등 지난주 급등한 중형주 11종목 (4월 28일~5월 2일)

ODDITY Tech Ltd. - Class A Ordinary Shares

ODDITY Tech Ltd

ODD BURGER CORPORATION by Odd Burger Corporation

Odd Burger Corp

Pacer BlueStar Digital Entertainment ETF

Oddz

Keefe, Bruyette &amp; Woods analyst Brady Gailey maintains Prosperity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PB#NYSE">PB</a>) with a Outperform and lowers the price target from $95 to $90.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Outperform on Prosperity Bancshares, Lowers Price Target to $90

Wells Fargo analyst Brandon Couillard maintains Mettler-Toledo Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) with a Equal-Weight and raises the price target from $1125 to $1200.

Wells Fargo Maintains Equal-Weight on Mettler-Toledo Intl, Raises Price Target to $1200

Biotech

Events

General

ASND

AscendisTto Share Data From Hypoparathyroidism, Achondroplasia, And Growth Hormone Deficiency Programs During ESPE & ESE 2025

FLUX

Flux Power Awarded Patent For Its Intelligent Battery Cycle Life Maximization Algorithm

Comscore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>), a global leader in measuring and analyzing consumer behaviors, today announced a new solution to address the inventory quality challenges facing advertisers. Comscore Certified Deal IDs, initially available through Magnite's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) supply-side platform (SSP), leverage Comscore's trusted content measurement rankings to offer advertisers a reliable path to high-quality programmatic inventory, enabling more effective campaign performance.
Comscore is activating Certified Deal IDs through Magnite due to the company's extensive direct relationships with premium media owners, covering 96% of overall omnichannel supply (Jounce March 2025 Supply Benchmarking Report).

MGNI

SCOR

Comscore Announces Certified Deal IDs in Magnite's SSP To Address Inventory Quality Challenges Facing Advertisers

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, "Following our recent uplisting to Nasdaq, we remain very pleased with the growth trajectory of our business as we conclude the first quarter of 2025 and enter the second quarter. We believe that we are well-positioned to maintain this momentum and achieve new and impactful milestones throughout 2025."
The Company reiterated:
<ul>
<li>14 SSi Mantra surgical robotic systems were installed during the first quarter of 2025, bringing the cumulative installed base to 78 as of March 31, 2025.</li>
<li>Revenue for the first quarter of 2025 is expected to be approximately $6.4 million with a gross margin of approximately 45%, based on preliminary unaudited results which are subject to change.</li>
</ul>
The Company also provided the following updates:
<ul>
<li>As of April 30, 2025, 80 SSi Mantra robotic surgical systems have been installed in 75 hospitals and more than 3800 surgeries have utilized the SSi Mantra, including over 200 robotic cardiac surgeries.</li>
<li>SSi Mantra robotic surgical system orders totaled 9 in the first month of the second quarter, April 2025, up 200% from 3 orders in April 2024.</li>
</ul>
The Company anticipates reporting first quarter 2025 financial results on or about May 15, 2025.

Guidance

SSII

SS Innovations Reiterates Q1 Guidance Of ~$6.4M; Says SSi Mantra Robotic Surgical System Orders Totaled 9 In The First Month Of Q2, April 2025, Up 200% From 3 Orders In April 2024

Alexander's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALX#NYSE">ALX</a>) reported quarterly earnings of $4.06 per share which beat the analyst consensus estimate of $3.57 by 13.73 percent. This is a 18.47 percent decrease over earnings of $4.98 per share from the same period last year. The company reported quarterly sales of $54.91 million which missed the analyst consensus estimate of $56.00 million by 1.94 percent. This is a 10.56 percent decrease over sales of $61.40 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Alexander's Q1 FFO $4.06 Beats $3.57 Estimate, Sales $54.91M Miss $56.00M Estimate

Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care

AMIX

Autonomix Medical Releases Testimonial From Patient Participating In Initial Phase Of Its First-in-human Proof-of-concept Trial Evaluating The Safety And Effectiveness Of Delivering Transvascular Energy To Ablate Relevant Nerves And Mitigate Pain In Patients With Severe Pancreatic Cancer Pain.

Wells Fargo analyst Michael Brown maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Equal-Weight and raises the price target from $20 to $21.5.

Wells Fargo Maintains Equal-Weight on Franklin Resources, Raises Price Target to $21.5

Wells Fargo analyst Jonathan Reeder maintains Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEP#NYSE">BEP</a>) with a Overweight and lowers the price target from $29 to $27.

Wells Fargo Maintains Overweight on Brookfield Renewable, Lowers Price Target to $27

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the financial sector.
<h3 class="wp-block-heading">Horizon Technology Finance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>)</h3>
<ul>
<li>Dividend Yield: 17.89%</li>
<li>Keefe, Bruyette &amp; Woods analyst Paul Johnson maintained an Underperform rating and cut the price target from $8 to $7.5 on April 8, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Compass Point analyst Casey Alexander upgraded the stock from Sell to Neutral with a price target of $8.25 on Dec. 17, 2024. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: On April 29, Horizon Technology Finance reported first-quarter financial results and missed its net and total investment income estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest HRZN <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505"><img loading="lazy" decoding="async" width="916" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050809/image-35.png" alt="" class="wp-image-900873" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050809/image-35.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050809/image-35-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050809/image-35-768x709.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">Ellington Credit Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>)</h3>
<ul>
<li>Dividend Yield: 17.78%</li>
<li>UBS analyst Douglas Harter maintained a Neutral rating and cut the price target from $6.5 to $5.25 on April 17, 2025. This analyst has an accuracy rate of 68%.</li>
<li>JMP Securities analyst Mikhail Goberman reiterated a Market Perform rating on April 19, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On April 3, Ellington Credit Company's Board of Trustees declared a monthly common dividend of $0.08 per share.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest EARN <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505"><img loading="lazy" decoding="async" width="912" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050844/image-2-14.png" alt="" class="wp-image-900876" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050844/image-2-14.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050844/image-2-14-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050844/image-2-14-768x713.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">AGNC Investment Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>)</h3>
<ul>
<li>Dividend Yield: 16.38%</li>
<li>RBC Capital analyst Kenneth Lee maintained an Outperform rating and cut the price target from $11 to $10 on April 29, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Wells Fargo analyst Donald Fandetti maintained an Overweight rating and slashed the price target from $11 to $10 on April 22, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: On April 21, AGNC Investment posted upbeat quarterly earnings.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest AGNC <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505"><img loading="lazy" decoding="async" width="915" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050916/image-36.png" alt="" class="wp-image-900878" style="width:597px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050916/image-36.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050916/image-36-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05050916/image-36-768x690.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Markets

Trading Ideas

AGNC

EARN

HRZN

Wall Street's Most Accurate Analysts Give Their Take On 3 Financial Stocks With Over 10% Dividend Yields

Valaris Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) ("Valaris" or the "Company") announced today that it has been awarded a five-well contract offshore West Africa for drillship VALARIS DS-15. The contract is expected to commence in the third quarter 2026. The total contract value, based on an estimated duration of 250 days, is approximately $135 million, including upfront payments for rig upgrades and mobilization. The total contract value does not include the provision of additional services. The contract includes priced options for up to five wells with an estimated total duration of 80 to 100 days.

Valaris Secures $135M, Five-Well Offshore West Africa Contract For Drillship VALARIS DS-15

Proposed Terms of Merger
By signing the Letter of Intent, this potential transaction marks a distinct shift in a positive direction for existing BioSig shareholders.
<ul>
<li>Immediately after the Merger, the current stockholders of Streamex will own approximately 19.9% of the outstanding Common Stock of the Company and a number of Series X Convertible Preferred Stock, par value $0.0001 per share ("Series X"), such that after taking into account the conversion of the Series X, the former stockholders of Streamex will own approximately 75% of the outstanding Common Stock of the Company, with the Company's current stakeholders owning the remaining equity of the Company.</li>
</ul>

BSGM

BioSig Enters LOI To Merge With Streamex Exchange Corp; Current Stockholders Of Streamex Will Own ~19.9% Of Outstanding Common Stock Of Co. And A Number Of Series X Convertible Preferred Stock

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Vikram Purohit upgraded the rating for Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) from Equal-Weight to Overweight and raised the price target from $180 to $250. Ascendis Pharma shares closed at $172.06 on Friday. <a href="https://www.benzinga.com/quote/ASND/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Brian McNamara upgraded Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) from Hold to Buy and boosted the price target from $54 to $67. Worthington Enterprises shares closed at $51.99 on Friday. <a href="https://www.benzinga.com/quote/WOR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC analyst Stephen Bersey upgraded Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) from Reduce to Hold and raised the price target from $77 to $99. Twilio shares closed at $100.11 on Friday. <a href="https://www.benzinga.com/quote/TWLO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst John Ivankoe upgraded the rating for The Wendy&#8217;s Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) from Neutral to Overweight but lowered the price target from $17 to $15. Wendy&#8217;s shares closed at $12.55 on Friday. <a href="https://www.benzinga.com/quote/WEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Aaron Kessler upgraded Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) from Neutral to Buy and announced a $165 price target. Reddit shares closed at $113.83 on Friday. <a href="https://www.benzinga.com/quote/RDDT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TWLO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="567" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-1024x567.png" alt="" class="wp-image-901223" style="width:628px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-1024x567.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15-768x426.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05083045/image-2-15.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Upgrades

RDDT

TWLO

This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Wells Fargo analyst Jonathan Reeder maintains Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEPC#NYSE">BEPC</a>) with a Overweight and lowers the price target from $33 to $32.

BEPC

Wells Fargo Maintains Overweight on Brookfield Renewable, Lowers Price Target to $32

The U.S. Food and Drug Administration (FDA) on Monday cleared Lantern Pharma Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) Investigational New Drug Application (IND) for a Phase 1b/2 trial for LP-184 in triple-negative <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">breast cancer (TNBC)</a>.
The dual approach in the clinical trial is designed to evaluate LP-184 in recurrent, advanced-stage TNBC patients through:
<ul>
<li>Monotherapy Arm: An open-label study involving approximately 30 patients with advanced-stage TNBC, focusing on dose optimization to evaluate, enhance, and optimize safety and potential efficacy for TNBC patients.</li>
<li>Combination Therapy: Evaluation of LP-184 in combination with olaparib in second-line settings for patients with advanced-stage TNBC harboring BRCA1 or BRCA2 alterations, with primary endpoints including safety and efficacy parameters that could support a pathway to regulatory approval.In preclinical studies, treating an animal model with BRCA-1 LOH and an HRD score of 63 resistant to the PARP inhibitor showed evidence of resensitization in combination with LP-184.</li>
<li>The combination phase 1b/2 trial design provides for LP-184 to be evaluated in a second-line setting in patients with advanced-stage TNBC whose primary tumor harbors alterations in BRCA1 or BRCA2.</li>
</ul>
In 2024, LP-184 received Fast Track Designations from the FDA for GBM (Glioblastoma Multiforme)&nbsp;and&nbsp;TNBC.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43741954/small-cap-os-therapies-inks-commercial-manufacture-agreements-for-its-lead-cancer-drug-for-rare-type-of-bone-cancer" rel="noreferrer noopener">Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer</a>
Additionally,&nbsp;LP-184 received three Rare Pediatric Disease Designations&nbsp;for hepatoblastoma, rhabdomyosarcoma, and malignant rhabdoid tumors, in addition to its existing designation for ATRT, an ultra-rare pediatric brain tumor with the genetic hallmark of loss-of-function or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44523410/lantern-pharma-provides-business-updates-and-fourth-quarter-year-end-2024-financial-results" rel="noreferrer noopener">deletion of the SMARCB1 gene</a>.
Lantern is conducting a Phase 1a trial that is on cohort 11, and early indications of clinical activity have been observed at higher dose levels, consistent <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44523410/lantern-pharma-provides-business-updates-and-fourth-quarter-year-end-2024-financial-results" rel="noreferrer noopener">with preliminary PK data</a>.
<ul>
<li>Dose levels 7, 8, and 9 were cleared without safety concerns during Q4 of 2024, and preliminary PK data suggest dose proportionality with exposure.</li>
<li>Enrollment at dose levels 9 and above is focused on including advanced solid tumor patients who have identified DNA damage repair mutations.</li>
<li>A broader clinical data update is slated for Q2 2025, when recruitment for the trial is expected to be finished, and complete safety and dose-response data are expected to be available.</li>
</ul>
The global TNBC market is estimated at $3-$5 billion annually, with over 300,000 new cases diagnosed worldwide yearly. While homologous recombination-deficient TNBCs are often initially treated with PARP inhibitors, resistance inevitably develops, underscoring the critical need for novel therapeutic approaches.
Price Action: LTRN stock closed at $3.54 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45179856/alnylam-delivers-q1-surprise-analysts-highlight-amvuttra-momentum-and-limited-tariff-risk" target="_blank" rel="noreferrer noopener">Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

LTRN

EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial

Rand Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAND#NASDAQ">RAND</a>) reported quarterly earnings of $0.40 per share. This is a 8.11 percent increase over earnings of $0.37 per share from the same period last year. The company reported $2.01 million in sales this quarter. This is a 2.85 percent decrease over sales of $2.07 million the same period last year.

RAND

Rand Capital Q1 Adj. EPS $0.40 Up From $0.37 YoY, Sales $2.01M Down From $2.07M YoY

Wells Fargo analyst Roger Read maintains Shell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) with a Overweight and lowers the price target from $83 to $80.

SHEL

Wells Fargo Maintains Overweight on Shell, Lowers Price Target to $80

Wells Fargo analyst Roger Read maintains Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) with a Overweight and lowers the price target from $173 to $164.

Wells Fargo Maintains Overweight on Chevron, Lowers Price Target to $164

EXCLUSIVE: Lantern Pharma Tells Benzinga ''The phase 1b/2 clinical trial plans to evaluate LP-184 in recurrent TNBC patients as both monotherapy and in combination with olaparib'

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ODDITY Tech Ltd. of Class Action Lawsuit and Upcoming Deadlines - ODD

ODDITY to Announce Third Quarter 2024 Financial Results on November 6, 2024

Oddity Tech Reports Record Third Quarter Results, Raises Outlook

L Catterton Agrees to Sell $100 Million of Shares Back to ODDITY

ODDITY Acquires Intellectual Property and Elite AI Research Team to Accelerate AI Capabilities

Financing

ODDITY Announces New $200 Million Credit Facility

ODDITY to Announce Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Oddity Tech Reports Record 2024 Fourth Quarter and Full Year Results

ODDITY to Announce First Quarter 2025 Financial Results on April 29, 2025

ODDITY Tech Reports Record First Quarter Results, Raises Full Year Outlook

Goldman Sachs

Truist Securities

JP Morgan

JMP Securities

Keybanc

지난주 가장 좋은 성과를 거든 중형주는 다음과 같다.
<ol>
<li>포니AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>)는 회사가 수익성에 가까워지고 있으며 <a href="https://www.benzinga.com//node/45049945" target="_blank" rel="noreferrer noopener">자율주행 시스템을 더 저렴하게 구축할 수 있다고 발표한 후</a> 주가가 48.36% 상승했다.</li>
<li>힘스 앤 헐스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) 주가는 회사가 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)와 협력하여 <a href="https://www.benzinga.com//node/45074872" target="_blank" rel="noreferrer noopener">위고비의 모든 용량 패키지를 플랫폼에서 제공하기로 발표</a>한 후 45.32% 급등했다. 뱅크오브아메리카 증권의 애널리스트는 <a href="https://www.benzinga.com/quote/hims/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 22달러에서 26달러로 상향 조정</a>했다.</li>
<li>오디티 테크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) 주가는 회사가 기대 이상의 1분기 재무 결과를 발표하고 FY25 가이던스를 상향 조정하며 <a href="https://www.benzinga.com//node/45111584" target="_blank" rel="noreferrer noopener">2분기 가이던스를 예상치를 초과하여 발표</a>한 후 42.96% 급등했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/ODD/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 상향 조정</a>했다.</li>
<li>멧세라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) 주가는 지난 주 38.42% 상승했다.</li>
<li>CG 온콜로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) 주가는 회사가 크레토스티모진 그레나데노렙벡(cretostimogene grenadenorepvec) 단일요법 데이터를 미국 <a href="https://www.benzinga.com//node/45043205" target="_blank" rel="noreferrer noopener">비뇨기과학회 연례 회의에서 발표했다고 공개</a>한 후 29.86% 상승했다. 일부 애널리스트들은 커버리지를 개시하거나<a href="https://www.benzinga.com/quote/cgon/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 상향 조정</a>했다.</li>
<li>키닉사 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) 주가는 FY25 매출 가이던스를 <a href="https://www.benzinga.com//node/45063476" target="_blank" rel="noreferrer noopener">상향 조정</a>한 후 29.42% 상승했다.</li>
<li>킹소프트 클라우드 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) 주가는 27.34% 상승했다.</li>
<li>프론트도어(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) 주가는 회사가 기대 이상의 1분기 재무 결과를 발표하고 FY25 <a href="https://www.benzinga.com//node/45130988" target="_blank" rel="noreferrer noopener">매출 전망을 상향 조정</a>한 후 25.44% 상승했다.</li>
<li>ATI(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) 주가는 기대 이상의 분기 재무 결과를 보고하고 FY25 <a href="https://www.benzinga.com//node/45130989" target="_blank" rel="noreferrer noopener">조정 EPS 가이던스를 상향 조정한 후</a> 25.39% 상승했다.</li>
<li>퍼도세오 에듀케이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDO#NASDAQ">PRDO</a>) 주가는 <a href="https://www.benzinga.com//node/45149554" target="_blank" rel="noreferrer noopener">1분기 결과를 발표</a>한 후 23.72% 상승했다.</li>
<li>아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) 주가는 기대 이상의 1분기 결과를 발표하고 <a href="https://www.benzinga.com//node/45149802" target="_blank" rel="noreferrer noopener">FY25 매출 가이던스를 상향 조정</a>한 후 23.71% 급등했다.</li>
</ol>
사진 출처: Tada Images via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

ODDITY Tech

뉴스

에 대한 최신 뉴스 ODDITY Tech (NASDAQ:ODD) 주식

일요일, 5월 04, 2025

뉴스

파트너 / 기고자

벤징가 글로벌